Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 4, Issue 9, pp. 1046-1061
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 31, 2014
- Revision received June 1, 2014
- Accepted June 2, 2014
- Published first June 3, 2014.
Article Versions
- Previous version (June 3, 2014 - 06:46).
- Previous version (June 5, 2014 - 07:30).
- Previous version (August 11, 2014 - 08:07).
- You are viewing the most recent version of this article.
Copyright & Usage
©2014 American Association for Cancer Research.
Author Information
- Darren A.E. Cross1,*,
- Susan E. Ashton1,
- Serban Ghiorghiu1,
- Cath Eberlein1,
- Caroline A. Nebhan4,
- Paula J. Spitzler4,
- Jonathon P. Orme2,
- M. Raymond V. Finlay1,
- Richard A. Ward1,
- Martine J. Mellor1,
- Gareth Hughes1,
- Amar Rahi1,
- Vivien N. Jacobs1,
- Monica Red Brewer4,
- Eiki Ichihara4,
- Jing Sun4,
- Hailing Jin4,
- Peter Ballard1,
- Katherine Al-Kadhimi1,
- Rachel Rowlinson1,
- Teresa Klinowska1,
- Graham H.P. Richmond1,
- Mireille Cantarini1,
- Dong-Wan Kim5,
- Malcolm R. Ranson3 and
- William Pao4,*
- 1Oncology Innovative Medicines and
- 2Discovery Sciences, AstraZeneca, Macclesfield Cheshire;
- 3University of Manchester, Christie Hospital, Manchester, United Kingdom;
- 4Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and
- 5Seoul National University Hospital, Seoul, Republic of Korea
- ↵*Corresponding Authors:
Darren Cross, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom. Phone: 44-1625-515649; E-mail: Darren.Cross{at}astrazeneca.com; and William Pao, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232. Phone: 615-343-9454; Fax: 615-343-7602; E-mail: william.pao{at}vanderbilt.edu
September 2014
Volume 4, Issue 9
Volume 4, Issue 9
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Jump to section
Advertisement